AMZN 1.97TSM -12.53CMS 0.35MURGF 0MSFT 5.89FNV.TO -7.36NVDA -7.43LLY -6.71
Abbott Labs (ABT)

NYSE:ABT

Abbott Labs (ABT)

92.11
-1.82 (1.94%)
as of Jul 13, 2026, 8:00:00 pm Market Open.
355 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 13, 2026, 12:00 am

This summary was created by AI, based on 16 opinions in the last 12 months.

Abbott Labs (ABT) has faced a challenging year, witnessing nearly a 30% decline in stock price amid lowered earnings guidance and increased competition, particularly in the diagnostics and medical devices sectors. The company's recent acquisition in cancer treatment presents a potential long-term growth opportunity, although it is not expected to be immediately accretive to earnings. Despite these hurdles, analysts emphasize the company's strong fundamentals, including a solid balance sheet and high organic growth rates in core businesses. The stock is currently trading below historical PE ratios, making it appealing for investors seeking stability and dividend income. Many experts express cautious optimism, highlighting the potential for recovery as demographic trends favor the healthcare sector.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
ALC
COMMENT

Abbott Labs(ABT)

Jan 14, 2010
Not hot on pharmaceuticals because of generic manufacturing and litigation risks. This one is a pretty good choice in pharmaceuticals with a pretty good product line up going forward. A lower risk way to play pharmaceuticals is through Johnson & Johnson (JNJ-N) that has both pharmaceuticals and branded consumer products.
Photo of David BaskinDavid BaskinUnlock Rating
$55.35

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jan 13, 2010
Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$55.29

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jul 08, 2009
Medical company, pharma and diagnostics. Good solid holding. Pays a good dividend. Good core holding for a portfolio.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$46.31

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Nov 21, 2008
Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
Photo of Walter GerasimowiczWalter Gerasimowicz
Owned
Unlock Rating
$51.52

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Aug 29, 2007
In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
Photo of Norman LevineNorman LevineUnlock Rating
$51.49

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Aug 25, 2005
Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$45.11

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

May 21, 2004
Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
Photo of Harvey EisenHarvey Eisen
Owned
Unlock Rating
$40.00

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 30, 2004
Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals.
Photo of David KingDavid KingUnlock Rating
$44.02

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Sep 03, 2003
Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive.
Photo of Brad WillockBrad WillockUnlock Rating
$41.75

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Dec 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
Photo of David BurrowsDavid BurrowsUnlock Rating
$55.50

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jan 08, 2001
Getting into acquisitions. Had to restructure. Moving from a value to a growth stock
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$42.56

Stock price when the opinion was issued

$92.11

As of Jul 13, 2026. Market Open.

biotechnologypharmaceutical
Showing 211 to 221 of 221 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

WMT 0.88$114.78
MOS 0.8$22.31
DOW 1.34$30.37
VLO 15.1$295.79
SBP 0$

Today's Top Picks

AMZN 1.97$247.31
TSM -12.53$421.58
CMS 0.35$75.75
MURGF 0$573.703
MSFT 5.89$390.99

Popular Articles

Latest Sell Signals

DUOL 7.58$132.34
NVDA -7.43$203.53
STN.TO -0.79$97.29
ATRL.TO -0.93$88.13
WSP.TO 0.17$173

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like